T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.
Toni K. Choueiri,Ulka N. Vaishampayan,Jonathan E. Rosenberg,Theodore F. Logan,Andrea L. Harzstark,Brian I. Rini,Sandy Srinivas,Laurel M. Adams,Laurie Sherman,Lone Ottesen,David F. McDermott,Donald P. Bottaro,W. Marston Linehan,Ramaprasad Srinivasan +13 more
TL;DR: In the largest clinical trial devoted to papillary RCC, foretinib demonstrated anti-tumor activity in patients with PRC, modulation of several target indicator plasma proteins, and a manageable toxicity profile.
Journal ArticleDOI
The impact of Medicare eligibility on cancer screening behaviors.
Christian Meyer,Christopher B. Allard,Jesse D. Sammon,Julian Hanske,Julia McNabb-Baltar,Joel E. Goldberg,Gally Reznor,Stuart R. Lipsitz,Toni K. Choueiri,Paul L. Nguyen,Joel S. Weissman,Quoc-Dien Trinh +11 more
TL;DR: Medicare eligibility impacts the prevalence of cancer screening, likely as a result of increased access to primary care, and low-income individuals benefit most from Medicare eligibility.
Journal ArticleDOI
MET as a target in papillary renal cell carcinoma.
TL;DR: The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors.
Journal ArticleDOI
Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010.
Alexander P. Cole,Deepansh Dalela,Julian Hanske,Stephanie A. Mullane,Toni K. Choueiri,Christian Meyer,Paul L. Nguyen,Mani Menon,Adam S. Kibel,Mark A. Preston,Joaquim Bellmunt,Quoc-Dien Trinh +11 more
TL;DR: Adequacy of pelvic LND remains an important measure of surgical quality in bladder cancer and the likelihood of receiving an adequate LND has increased substantially; however, a substantial minority of patients still does not receive LND.
Journal ArticleDOI
Recent advances in immunotherapy for the treatment of prostate cancer.
TL;DR: The clinical benefit of combining vaccines with chemotherapy, radiotherapy and other immunotherapeutic and biologic agents is being evaluated in the context of disappointing results of combination GVAX vaccine and docetaxel chemotherapy.